Table 1.

Efficacy of SARS CoV-2 Vaccines by Age Group in Phase III Clinical Trials

Vaccine	Type	Doses (interval)	Median Follow-up	Age Groups	N (vaccine vs placebo)	Efficacy (95% CI)	Primary Efficacy Outcome	Ref.
BioNTech/Pfizer BNT162b2	mRNA	2 (3 weeks)	2 months	All 16–55 > 55	18,198 vs 18,325 10,889 vs 10,896 7971 vs 7950	95.0 (90.0–97.9) 95.6 (89.4–98.5) 93.7 (80.6–98.8)	Confirmed CoVID-19 (symptoms in combination with PCR test)	[46]
Moderna mRNA-1273	mRNA	2 (4 weeks)	63 days	All 18–64 > 64	14,134 vs 14,073 10,551 vs 10,521 3583 vs 3552	94.1 (89.3–96.8) 95.6 (90.6–97.9) 86.4 (61.4–95.2)	Symptomatic Covid-19 with onset at least 14 days after the second injection	[47]
Janssen Ad26.COV2-S	Viral vector	1	58 days	All 18–59 > 59	21,895 vs 21,888 14,564 vs 14,547 7331 vs 7341	66.9 (59.0–73.4) 63.7 (53.9–71.6) 76.3 (61.6–89.0)	Moderate to severe–critical Covid-19	[48]
AstraZeneca/Oxford ChAdOx1	Viral vector	2 (4–12 weeks)	61 days	All 18–64 > 64	21,587 vs 10.792 16,760 vs 8381 4827 vs 2411	74.0 (65.3–80.5) 72.8 (63.4–79.9) 83.5 (54.2–94.1)	Symptomatic illness	[49]